Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV Prophylaxis in Lung Transplant
NCT06057194Phase 2Not yet recruiting
- Sponsor
- Maimónides Institute of Biomedical Research of Córdoba
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Maimónides Institute of Biomedical Research of Córdoba. Primary endpoint: Incidence of CMV disease/replication at 12 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06057194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057194.